How The ACCESS Consortium’s New ‘Promise Pathway’ Can Benefit Drugmakers

 
• By Eliza Slawther

Pharmaceutical companies that develop new medicines for life-threatening or severely debilitating conditions could be eligible to file for a priority review in the five ACCESS Consortium member countries under a new pilot scheme.

Sand running through the bulbs of an hourglass measuring the passing time in a countdown to a deadline, on a dark background with copy space.

More from International

More from Geography